{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T01:52:25Z","timestamp":1768528345983,"version":"3.49.0"},"reference-count":55,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Science Centre","award":["[2022\/06\/X\/NZ5\/01813]"],"award-info":[{"award-number":["[2022\/06\/X\/NZ5\/01813]"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Gastric cancer (GC) is one of the most frequently diagnosed cancers in the world. Although the incidence is decreasing in developed countries, the treatment results are still unsatisfactory. The standard treatment for locally advanced gastric cancer (LAGC) is gastrectomy with perioperative chemotherapy. The association of selected microRNAs (miRNAs) with chemoresistance was assessed using archival material of patients with LAGC. Histological material was obtained from each patient via a biopsy performed during gastroscopy and then after surgery, which was preceded by four cycles of neoadjuvant chemotherapy (NAC) according to the FLOT or FLO regimen. The expression of selected miRNAs in the tissue material was assessed, including miRNA-21-3p, miRNA-21-5p, miRNA-106a-5p, miRNA-122-3p, miRNA-122-5p, miRNA-143-3p, miRNA-143-5p, miRNA-203a-3p, miRNA-203-5p, miRNA-551b-3p, miRNA-551b-5p, and miRNA-574-3p. miRNA expression was assessed using quantitative reverse transcription polymerase chain reaction (qRT-PCR). The response to NAC was assessed using computed tomography of the abdomen and chest and histopathology after gastrectomy. The statistical analyses were performed using GraphPad Prism 9. The significance limit was set at p &lt; 0.05. We showed that the expression of miR-143-3p, miR-143-5p, and miR-574-3p before surgery, and miR-143-5p and miR-574-3p after surgery, decreased in patients with GC. The expression of miR-143-3p, miR-143-5p, miR-203a-3p, and miR-551b-5p decreased in several patients who responded to NAC. The miRNA most commonly expressed in these cases was miRNA-551b-5p. Moreover, it showed expression in a patient whose response to chemotherapy was inconsistent between the histopathological results and computed tomography. The expression of miR-143-3p, miR-143-5p, miR-203a-3p, and miR-551b-5p in formalin-fixed paraffin-embedded tissue (FFPET) samples can help differentiate between the responders and non-responders to NAC in LAGC. miR-143-3p, miR-143-5p, and miR-574-3p expression may be used as a potential diagnostic tool in GC patients. The presence of miR-551b-5p may support the correct assessment of a response to NAC in GC via CT.<\/jats:p>","DOI":"10.3390\/ijms25158057","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T15:47:32Z","timestamp":1721836052000},"page":"8057","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Diagnostic Potential of miR-143-5p, miR-143-3p, miR-551b-5p, and miR-574-3p in Chemoresistance of Locally Advanced Gastric Cancer: A Preliminary Study"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1238-5273","authenticated-orcid":false,"given":"Marlena","family":"Janiczek-Polewska","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, Greater Poland Cancer Centre, 61-866 Poznan, Poland"},{"name":"Department of Electroradiology, Poznan University of Medical Sciences, 61-701 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5623-7398","authenticated-orcid":false,"given":"Tomasz","family":"Kolenda","sequence":"additional","affiliation":[{"name":"Laboratory of Cancer Genetics, Greater Poland Cancer Centre, 61-866 Poznan, Poland"},{"name":"Research and Implementation Unit, Greater Poland Cancer Centre, 61-866 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulina","family":"Poter","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Poznan University of Medical Sciences and Greater Poland Cancer Centre, 61-866 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-4852","authenticated-orcid":false,"given":"Joanna","family":"Koz\u0142owska-Mas\u0142o\u0144","sequence":"additional","affiliation":[{"name":"Laboratory of Cancer Genetics, Greater Poland Cancer Centre, 61-866 Poznan, Poland"},{"name":"Research and Implementation Unit, Greater Poland Cancer Centre, 61-866 Poznan, Poland"},{"name":"Institute of Human Biology and Evolution, Faculty of Biology, Adam Mickiewicz University, 61-614 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inga","family":"Jagie\u0142\u0142o","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Poznan University of Medical Sciences and Greater Poland Cancer Centre, 61-866 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9584-3128","authenticated-orcid":false,"given":"Katarzyna","family":"Regulska","sequence":"additional","affiliation":[{"name":"Research and Implementation Unit, Greater Poland Cancer Centre, 61-866 Poznan, Poland"},{"name":"Pharmacy, Greater Poland Cancer Centre, 61-866 Poznan, Poland"},{"name":"Department of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences, Collegium Pharmaceuticum, 60-806 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5558-5558","authenticated-orcid":false,"given":"Julian","family":"Malicki","sequence":"additional","affiliation":[{"name":"Department of Electroradiology, Poznan University of Medical Sciences, 61-701 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-9151","authenticated-orcid":false,"given":"Andrzej","family":"Marsza\u0142ek","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Poznan University of Medical Sciences and Greater Poland Cancer Centre, 61-866 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): Analysis of individual records for 37\u2008513\u2008025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/gutjnl-2019-320234","article-title":"Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035","volume":"69","author":"Arnold","year":"2020","journal-title":"Gut"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(19)30456-5","article-title":"Progress in cancer survival, mortality, and incidence in seven high-income countries 1995\u20132014 (ICBP SURVMARK-2): A population-based study","volume":"20","author":"Arnold","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11912-019-0820-4","article-title":"Updates on Management of Gastric Cancer","volume":"21","author":"Johnston","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.4103\/jfmpc.jfmpc_527_20","article-title":"Gastric carcinoma: Insights into risk factors, methods of diagnosis, possible lines of management, and the role of primary care","volume":"9","author":"Marghalani","year":"2020","journal-title":"J. Fam. Med. Prim. Care"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"316","DOI":"10.5603\/RPOR.a2021.0024","article-title":"Second line of treatment for HER2-positive gastric cancer: An evolving issue","volume":"26","author":"Roviello","year":"2021","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/JCO.2017.35.15_suppl.4004","article-title":"Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil\/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF\/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial","volume":"35","author":"Homann","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2\/3 trial","volume":"393","author":"Homann","year":"2019","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.5603\/RPOR.a2021.0040","article-title":"Chemoradiotherapy or chemotherapy as adjuvant treatment for resected gastric cancer: Should we use selection criteria?","volume":"26","author":"Mansouri","year":"2021","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_12","first-page":"500","article-title":"Dose-escalated neoadjuvant chemoradiotherapy for locally advanced oesophageal or oesophagogastric junctional adenocarcinoma","volume":"27","author":"Campos","year":"2022","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/j.ejso.2019.03.040","article-title":"Poor compliance with perioperative chemotherapy for resectable gastric cancer and its impact on survival","volume":"45","author":"Lemmens","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1245\/s10434-020-09045-w","article-title":"Analysis of the Survival Impact of Postoperative Chemotherapy After Preoperative Chemotherapy and Resection for Gastric Cancer","volume":"28","author":"Drake","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Bukowski, K., Kciuk, M., and Kontek, R. (2020). Mechanisms of multidrug resistance in cancer chemotherapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093233"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4251\/wjgo.v12.i1.37","article-title":"Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines","volume":"12","author":"Wang","year":"2020","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"270","DOI":"10.23736\/S0026-4806.19.05972-X","article-title":"Long non-coding RNA XIST contributes into drug resistance of gastric cancer cell","volume":"110","author":"Li","year":"2019","journal-title":"Minerva Medica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.rpor.2020.07.006","article-title":"Good or not good: Role of miR-18a in cancer biology","volume":"25","author":"Kolenda","year":"2020","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Plotnikova, O., Baranova, A., and Skoblov, M. (2019). Comprehensive Analysis of Human microRNA\u2013mRNA Interactome. Front. Genet., 10.","DOI":"10.3389\/fgene.2019.00933"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"114","DOI":"10.5603\/RPOR.a2023.0006","article-title":"Host gene and its guest: Short story about relation of long-noncoding MIR31HG transcript and microRNA miR-31","volume":"28","author":"Kolenda","year":"2023","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.5603\/RPOR.a2022.0123","article-title":"Midsize noncoding RNAs in cancers: A new division that clarifies the world of noncoding RNA or an unnecessary chaos?","volume":"27","author":"Guglas","year":"2022","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kipkeeva, F., Muzaffarova, T., Korotaeva, A., Nikulin, M., Grishina, K., Mansorunov, D., and Karpukhin, A. (2020). MicroRNA in gastric cancer development: Mechanisms and biomarkers. Diagnostics, 10.","DOI":"10.3390\/diagnostics10110891"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrg1379","article-title":"MicroRNAs: Small RNAs with a big role in gene regulation","volume":"5","author":"He","year":"2004","journal-title":"Nat. Rev. Genet."},{"key":"ref_24","first-page":"681","article-title":"miRNA in head and neck squamous cell carcinomas: Promising but still distant future of personalized oncology","volume":"28","author":"Guglas","year":"2023","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Howe, K. (2017). Extraction of miRNAs from Formalin-Fixed Paraffin-Embedded (FFPE) tissues. Methods in Molecular Biology, Humana Press Inc.","DOI":"10.1007\/978-1-4939-6524-3_3"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/1096-9896(200109)195:1<66::AID-PATH921>3.0.CO;2-F","article-title":"Unlocking the archive\u2014Gene expression in paraffin-embedded tissue","volume":"195","author":"Lewis","year":"2001","journal-title":"J. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"13658","DOI":"10.3748\/wjg.v20.i38.13658","article-title":"MicroRNAs: Promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential","volume":"20","author":"Matuszcak","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Riquelme, I., Letelier, P., Riffo-Campos, A.L., Brebi, P., and Roa, J.C. (2016). Emerging role of mirnas in the drug resistance of gastric cancer. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17030424"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Zeng, Z., Wang, J., Zhao, L., Hu, P., Zhang, H., Tang, X., and Zeng, Z. (2013). Potential Role of microRNA-21 in the Diagnosis of Gastric Cancer: A Meta-Analysis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0073278"},{"key":"ref_30","first-page":"907","article-title":"C miR-21 MicroRNA Expression in Human Gastric Carcinomas and its Clinical Association","volume":"28","author":"Chan","year":"2008","journal-title":"Anticancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.tox.2013.02.014","article-title":"MiR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN","volume":"306","author":"Yang","year":"2013","journal-title":"Toxicology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12013-014-0450-2","article-title":"Antagonism of miRNA-21 Sensitizes Human Gastric Cancer Cells to Paclitaxel","volume":"72","author":"Jin","year":"2015","journal-title":"Cell Biochem. Biophys."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12957-021-02313-3","article-title":"The value of restaging CT following neoadjuvant chemotherapy for resectable gastric cancer. A population-based study","volume":"19","author":"Fougner","year":"2021","journal-title":"World J. Surg. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Dong, S., Zhang, X., and Liu, D. (2019). Overexpression of long noncoding RNA GAS5 suppresses tumorigenesis and development of gastric cancer by sponging miR-106a-5p through the Akt\/mTOR pathway. Biol. Open, 8.","DOI":"10.1101\/510511"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/abbs\/gmt106","article-title":"MiR-106a confers cisplatin resistance by regulating PTEN\/Akt pathway in gastric cancer cells","volume":"45","author":"Fang","year":"2013","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_36","first-page":"323","article-title":"TFAP2E methylation promotes 5-fluorouracil resistance via exosomal miR-106a-5p and miR-421 in gastric cancer MGC-803 cells","volume":"20","author":"Jingyue","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/abbs\/gmz141","article-title":"MiR-122-5p suppresses the proliferation migration invasion of gastric cancer cells by targeting, L.Y.N","volume":"52","author":"Meng","year":"2020","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"22485","DOI":"10.1002\/jcp.28812","article-title":"Chemoresistance in gastric cancer is attributed to the overexpression of excision repair cross-complementing 1 (ERCC1) caused by microRNA-122 dysregulation","volume":"234","author":"Song","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_39","first-page":"183","article-title":"Restoration of miRNA-143 Expression Inhibits Growth and Migration of MKN-45 Gastric Cancer Cell Line","volume":"12","author":"Hosseinahli","year":"2022","journal-title":"Adv. Pharm. Bull."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1007\/s13277-014-2898-5","article-title":"Involvement of miR-143 in cisplatin resistance of gastric cancer cells via targeting IGF1R and BCL2","volume":"36","author":"Zhuang","year":"2015","journal-title":"Tumor Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.biopha.2015.08.005","article-title":"MicroRNA-143 enhances chemosensitivity of Quercetin through autophagy inhibition via target GABARAPL1 in gastric cancer cells","volume":"74","author":"Du","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"28711","DOI":"10.18632\/oncotarget.15646","article-title":"MicroRNA-143-3p, up-regulated in H. pylori-positive gastric cancer, suppresses tumor growth, migration and invasion by directly targeting AKT2","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"10119","DOI":"10.1038\/s41598-018-27583-y","article-title":"MiR-99b-5p and miR-203a-3p function as tumor suppressors by targeting IGF-1R in gastric cancer","volume":"8","author":"Wang","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6093","DOI":"10.2147\/OTT.S197539","article-title":"MiR-203 acts as a radiosensitizer of gastric cancer cells by directly targeting ZEB1","volume":"12","author":"Jiang","year":"2019","journal-title":"OncoTargets Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"v8","DOI":"10.1093\/annonc\/mdz238.026","article-title":"LncRNA-GC1 contributes to gastric cancer chemo-resistance through inhibition of miR-551b-3p and the overexpression of dysbindin","volume":"30","author":"Guo","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"144383","DOI":"10.1016\/j.gene.2020.144383","article-title":"MicroRNA-574-5p in gastric cancer cells promotes angiogenesis by targeting protein tyrosine phosphatase non-receptor type 3 (PTPN3)","volume":"733","author":"Zhang","year":"2020","journal-title":"Gene"},{"key":"ref_47","first-page":"294","article-title":"A conserved family of prolyl-4-hydroxylases that modify HIF","volume":"2001","author":"Bruick","year":"1979","journal-title":"Science"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.gene.2019.03.043","article-title":"MicroRNA-574-3p regulates epithelial mesenchymal transition and cisplatin resistance via targeting ZEB1 in human gastric carcinoma cells","volume":"700","author":"Wang","year":"2019","journal-title":"Gene"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3892\/ol.2013.1428","article-title":"miRNA: The nemesis of gastric cancer (Review)","volume":"6","author":"Xu","year":"2013","journal-title":"Oncol. Lett."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1007\/s10620-021-07263-0","article-title":"MicroRNA-574-3p Regulates HIF-\u03b1 Isoforms Promoting Gastric Cancer Epithelial-Mesenchymal Transition via Targeting CUL2","volume":"67","author":"Ji","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Lamperska, K.M., Kolenda, T., Teresiak, A., Kowalik, A., Kruszyna-Mochalska, M., Jackowiak, W., and Kozlowski, P. (2017). Different levels of let-7d expression modulate response of FaDu cells to irradiation and chemotherapeutics. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0180265"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Guglas, K., Kolenda, T., Koz\u0142owska-Mas\u0142o\u0144, J., Severino, P., Teresiak, A., Bli\u017aniak, R., and Lamperska, K. (2023). The Impact of YRNAs on HNSCC and HPV Infection. Biomedicines, 11.","DOI":"10.3390\/biomedicines11030681"},{"key":"ref_53","unstructured":"(2024, June 07). Available online: https:\/\/www.thermofisher.com\/es\/es\/home\/life-science\/pcr\/real-time-pcr\/real-time-pcr-assays\/mirna-ncrna-taqman-assays.html?gclid=Cj0KCQjwsPCyBhD4ARIsAPaaRf2gjNp3MXKK0M3WXnwJtno3nH5JKHS5Dxt7gPsOiNHdVlV9WSGJVtoaAjlnEALw_wcB&ef_id=Cj0KCQjwsPCyBhD4ARIsAPaaRf2gjNp3MXKK0M3WXnwJtno3nH5JKHS5Dxt7gPsOiNHdVlV9WSGJVtoaAjlnEALw_wcB:G:s&s_kwcid=AL!3652!3!606132911486!p!!g!!microrna%20assay!17574808760!139287690658&cid=gsd_pcr_sbu_r03_co_cp1491_pjt9622_gsd00000_0se_gaw_rs_pur_&gad_source=1."},{"key":"ref_54","first-page":"245","article-title":"The RNA world: From experimental laboratory to \u201cin silico\u201d approach. Part 1: User friendly RNA expression databases portals","volume":"29","author":"Kolenda","year":"2024","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"255","DOI":"10.5603\/RPOR.a2023.0030","article-title":"Biological role and diagnostic utility of ribosomal protein L23a pseudogene 53 in cutaneous melanoma","volume":"28","author":"Kolenda","year":"2023","journal-title":"Rep. Pract. Oncol. Radiother."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/15\/8057\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:22:17Z","timestamp":1760109737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/15\/8057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":55,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["ijms25158057"],"URL":"https:\/\/doi.org\/10.3390\/ijms25158057","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]}}}